Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Clinical treatment programs – US	$ 49	$ 33
Total Revenues	49	33
Costs and Expenses:
Production costs		77
Research and development	2,052	1,036
General and administrative	2,292	2,072
Total Costs and Expenses	4,344	3,185
Operating loss	(4,295)	(3,152)
Gain (Loss) on investments	203	(934)
Interest and other income	199	45
Redeemable warrants valuation adjustment		31
(Loss) on sale of assets	(23)
Gain from sale of income tax operating losses	255	190
Net Loss	$ (3,661)	$ (3,820)
Basic and diluted loss per share	$ (0.08)	$ (0.08)
Weighted average shares outstanding basic and diluted	48,399,950	47,994,672